Fabrice Kolb

Fabrice A. Kolb, PhD, is the Head of Immunology at Coultreon Biopharma. Prior to joining Coultreon Biopharma, Dr. Kolb served as Head of Immunology Discovery at Galapagos NV (2019–2025), where he built a new pipeline of best-in-class drug discovery projects and advanced several candidates into clinical development.

From 2015 to 2019, he was an Immunology Project Leader at Roche Pharma Research and Early Development, working across both small and large molecule platforms. He contributed to the development of Piasky®, a Complement C5-targeting antibody now approved for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). During this time, he also oversaw the small molecule drug discovery strategy for autoimmune diseases.

Between 2006 and 2015, Dr. Kolb held various roles at the Novartis Institutes for Biomedical Research. Notably, he led the development of a protease inhibitor from target validation to proof-of-concept in a rare immunodermatological condition. He also played a key role in multiple autoimmune and oncology programs, including the identification and development of the Complement Factor B inhibitor Fabhalta®, now approved for the treatment of both PNH and Immunoglobulin A Nephropathy.

Dr. Kolb holds a PhD in Cellular and Molecular Biology from the University of Strasbourg, France.